Arovella Therapeutics LimitedASX: ALA

Quarterly Activities/Appendix 4C Cash Flow Report

· Issued by Arovella Therapeutics Limited via ASX

Filed with ASX · · 13 pages · English

Summary by 6ix AI

Financially, Arovella reported a cash balance at the end of the quarter and highlighted its focus on advancing both its blood cancer and solid tumor programs. The report outlines key milestones and expectations for the upcoming quarter, including the initiation of patient dosing in clinical trials.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 23 October 2026 APPENDIX 4C: QUARTER ENDED 30 SEPTEMBER 2026 Highlights for the quarter: • Reached clinical readiness, with the first two batches successfully manufactured and released for patient use during September 2026. •...

Arovella Therapeutics Limited on 6ix

Earlier from Arovella Therapeutics

Later from Arovella Therapeutics

All Arovella Therapeutics news releases